基本信息
views: 0
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Patrick Chames obtained his phD at the "University de la Méditerranée", Marseille, France in 1997 in the field of antibody engineering. From 1997 to 2001, he worked in the laboratory of phage display pioneer Hennie R. Hoogenboom where he isolated by phage display the first human antibody fragment specifically binding to a cancer related class I MHC complex (TCR-like antibodies). From 2001 to 2005, he worked for a french start-up company (Cellectis SA, Paris) in the field of genome engineering where he significantly contributed to the set up of an in vivo method, leading to the isolation of homing endonucleases capable of performing specific double strand break in a whole genome. In 2005 he accepted a permanent position for the French National center for research (CNRS). Since 2009, he is working for the French institute for health and medical research (INSERM, Marseille, France) in the field of therapeutic bispecific antibodies and blocking antibodies and is specialized in the use of single domain antibodies. Since 2012 he is a team leader in the Cancer Research Center of Marseille (CRCM).
Patrick Chames, CNRS Research Director
Head of Antibody Therapeutics and Immunotargeting team
Centre de Recherche en Cancérologie de Marseille (CRCM)
Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes
TPR2 U1068 Parc Scientifique de Luminy - Case 915 - 163 Avenue de Luminy 13288 Marseille Cedex 9 France - Tel : +33 4 91 82 88 33
https://www.crcm-marseille.fr/en/teams/research-teams/patrick-chames/
patrick.chames@inserm.fr
Born in Marseille on 01/10/1970, one child.
- Diplomas -
2015 HDR, Faculty of medecine, Aix-Marseille Univ, Marseille
1997 PhD in immunotechnology, Dr Daniel Baty’s lab, CNRS UPR 9027, Marseille. (special distinction from Université de la Méditerranée 1997)
1993 Engineer Diploma at INSA (National Institute of Applied Sciences), Toulouse, Dpt. GBAGM (Molecular Biology and Food Engineering). 3rd / 36
- Experience -
12- Group leader at CRCM, Marseille, Antibody therapeutics and Immunotargeting
09-12 Main scientist, CRCM, Marseille, domain antibody based therapeutics
05-09 Research scientist CNRS (National center for scientific research), LISM, Marseille, domain antibody based therapeutics
01-05 Project leader at Cellectis SA, Paris (www.cellectis.com): Directed evolution (phage display, in vivo yeast recombination) of Homing Endonucleases with tailored specificities
97-01 Four years of post doctoral training in the lab of Dr Hennie Hoogenboom, Maastricht, NL (EC grant): Selection of antibodies against specific class I MHC molecule-peptide complex for diagnostic and therapy of cancer
Research Interests
Papers共 35 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Journal of chemical information and modelingno. 11 (2024): 4436-4461
INTERNATIONAL JOURNAL OF NANOMEDICINE (2024): 633-650
Pierre-André Lafon,Mireille Elodie Tsitokana, Ugo Alenda, Clémentine Eva Philibert, Mathieu Oosterlaken, Marta Cimadevila, Jessica Monnic,Salomé Roux, Julie Bessié,Séverine Diem,Franck Vandermoere,Laurent Prézeau,
biorxiv(2024)
Biophysical Journalno. 8 (2019): 1516-1526
Methods in Molecular Biology (2018)
mag(2013)
Cited23Views0Bibtex
23
0
mag(2013)
Cited23Views0Bibtex
23
0
Sylvain Arnould,Patrick Chames, Phillippe Duchateau,Jeancharles Epinat,Emmanuel Lacroix,Frederic Paques
mag(2012)
Cited103Views0Bibtex
103
0
Load More
Author Statistics
#Papers: 53
#Citation: 2901
H-Index: 23
G-Index: 41
Sociability: 5
Diversity: 2
Activity: 6
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn